← Back to headlines
Novo Nordisk Shares Drop After Cardiovascular Drug Fails Trial
Novo Nordisk's stock plummeted by approximately 10% after its cardiovascular drug failed to meet expectations in a clinical trial. This disappointing research data has raised concerns among investors regarding the company's pipeline.
31 Jul, 07:21 — 31 Jul, 13:54
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (67/100)8 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left3
Left (3)
politikendr-dkcnbc
Center4
Center (4)
marketwatchFTvgbloomberg
Right1
Right (1)
berlingske
Far R
Geographic diversity— 4 regions17/34
US3Denmark3UK1Norway1
Sources
Showing 4 of 8 sources
bloombergHigh7h ago
European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump
European shares pared some of their Friday gains as a decline on Novo Nordisk A/S weighed on the market, countering a rally in tech stocks and another round of largely upbeat results.
By Macarena Muñoz and Julien Ponthus
Read full article →FTVery High1h ago
Novo Nordisk shares drop 10% after cardiovascular drug trial disappoints
Danish drugmaker has been trying to diversify beyond its blockbuster obesity treatments Wegovy and Ozempic
Read full article →cnbcMostly Factual3h ago
Novo Nordisk shares dive 9% after heart medicine fails trial
Read full article →marketwatchMostly Factual55m ago
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
By Nora Redmond
Read full article →Coverage Timeline
First report: bloomberg · 31 Jul, 07:21|Full coverage: 8 · 7h|Window: 7h
Left-leaningCenterRight-leaning
